Abstract

The overall aim of the Hematologic Oncology Project is to develop and test new and effective strategies for treating hematologic neoplasms using dose-intense approaches and biologic therapies.
The Specific Aims are: 1. To test novel dose-intense strategies for treating non-Hodgkin's lymphoma and myeloma with growth factor and stem cell support, and monitoring of minimal residual disease (Projects 2-1, 2-2, 2-3). 2. To develop and test a curative intent treatment for chronic lymphocytic leukemia with assessment of minimal residual disease (Project 2-3). 3. To develop new biologic therapies for hematologic neoplasia (Project 2- 7). Project 2-1 focuses on the development and application of a clonotypic PCR for monitoring of minimal residual disease and Project 2-2 examines a dose-intense approach to relapsed lymphoma with stem cell mobilization. Project 2-3 proposes a curative intent protocol for chronic lymphocytic leukemia with PCR determination of minimal residual disease. Project 2-4 examines a therapeutic approach to poor-risk acute myelogenous leukemia integrating chemotherapy concomitant with colony-stimulating factor treatment. Project 2-5 examines new chemotherapeutic and differentiating agents in hematologic oncology. These projects follow the overall themes of the Program Project grant and integrate closely with the Solid Tumor Oncology Program.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA005826-37S1
Application #
6299881
Study Section
Project Start
1999-05-01
Project End
2001-07-05
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
37
Fiscal Year
2000
Total Cost
$188,635
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Tedeschi, Philip M; Vazquez, Alexei; Kerrigan, John E et al. (2015) Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res 13:1361-6
Bell, Melanie L; Kenward, Michael G; Fairclough, Diane L et al. (2013) Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346:e8668
Zhou, Ping; Hoffman, James; Landau, Heather et al. (2012) Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 12:49-58
Rizvi, Naiyer A; Rusch, Valerie; Pao, William et al. (2011) Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 17:3500-6
Zhao, Binsheng; Oxnard, Geoffrey R; Moskowitz, Chaya S et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-53
Klimek, Virginia M; Fircanis, Sophia; Maslak, Peter et al. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826-32
Riely, Gregory J; Kris, Mark G; Zhao, Binsheng et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5
Zhao, Binsheng; Schwartz, Lawrence H; Moskowitz, Chaya S et al. (2006) Lung cancer: computerized quantification of tumor response--initial results. Radiology 241:892-8
Maslak, P; Chanel, S; Camacho, L H et al. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:212-7
Yankeelov, Thomas E; Rooney, William D; Huang, Wei et al. (2005) Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18:173-85

Showing the most recent 10 out of 39 publications